PRODUCT INFORMATION

XTANDI® 40 mg SOFT CAPSULES

NAME OF THE MEDICINE

Active ingredient: enzalutamide

Chemical structure:

\[
\begin{align*}
\text{Chemical name:} & \quad 4-\{3-[4\text{-cyano-3-(trifluoromethyl)phenyl]}\text{-}5,5\text{-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl}\}\text{-}2\text{-fluoro-N-methylbenzamide} \\
\text{Molecular formula:} & \quad \text{C}_{21}\text{H}_{16}\text{F}_{4}\text{N}_{4}\text{O}_{2}\text{S} \\
\text{CAS registry number:} & \quad 915087-33-1
\end{align*}
\]

DESCRIPTION

Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water.

XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl macrogolglycerides.

XTANDI contains the following inactive ingredients: caprylocaproyl macrogolglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerol, purified water, titanium dioxide. The soft capsules also contain OPACODE WB monogramming ink NSP-78-17827 BLACK.

PHARMACOLOGY

Pharmacology

Enzalutamide is an androgen receptor signalling inhibitor that blocks the androgen receptor signalling pathway. Enzalutamide competitively inhibits binding of androgens to androgen receptors, and consequently inhibits the nuclear translocation of these receptors and inhibits the
binding of androgen receptor to DNA. In vitro, enzalutamide treatment decreased proliferation and induced prostate cancer cell death. Decreased tumour growth was seen in a mouse prostate cancer xenograft model. In preclinical studies enzalutamide lacked androgen receptor agonist activity against several prostate cancer cell lines. The active metabolite, N-desmethyl enzalutamide, exhibited similar in vitro activity to enzalutamide in the inhibition of testosterone binding to the androgen receptor.

Pharmacokinetics

The pharmacokinetics of enzalutamide have been evaluated in prostate cancer patients and in healthy male subjects. The mean terminal half-life ($t_{1/2}$) for enzalutamide in patients after a single oral dose is 5.8 days (range 2.8 to 10.2 days), and steady state is achieved in approximately one month. With daily oral administration, enzalutamide accumulates approximately 8.3-fold relative to a single dose. Daily fluctuations in plasma concentrations are low (peak-to-trough ratio of 1.25). Clearance of enzalutamide is primarily via hepatic metabolism, producing an active metabolite that circulates at approximately the same plasma concentration as enzalutamide.

Absorption

Maximum plasma concentrations ($C_{\text{max}}$) of enzalutamide in patients are observed 1 to 2 hours after administration. Based on a mass balance study in humans, oral absorption of enzalutamide is estimated to be at least 84.2%. Enzalutamide is not a substrate of the efflux transporters P-gp or BCRP. At steady state, the mean $C_{\text{max}}$ values for enzalutamide and its active metabolite are 16.6 µg/mL (23% coefficient of variation [CV]) and 12.7 µg/mL (30% CV), respectively.

Food has no clinically significant effect on the extent of absorption. In clinical trials, XTANDI was administered without regard to food.

Distribution

The mean apparent volume of distribution ($V/F$) of enzalutamide in patients after a single oral dose is 110 L (29% CV). The volume of distribution of enzalutamide is greater than the volume of total body water, indicative of extensive extravascular distribution. Studies in rodents indicate that enzalutamide and its active metabolite can cross the blood brain barrier.

Enzalutamide is 97% to 98% bound to plasma proteins, primarily albumin. The active metabolite is 95% bound to plasma proteins.

Metabolism

Enzalutamide is extensively metabolized. There are two major metabolites in human plasma: N-desmethyl enzalutamide (active) and a carboxylic acid derivative (inactive). Enzalutamide is metabolized by CYP2C8 and to a lesser extent by CYP3A4/5 (see INTERACTIONS WITH OTHER MEDICINES), both of which play a role in the formation of the active metabolite.
Under conditions of clinical use, enzalutamide is a strong inducer of CYP3A4, a moderate inducer of CYP2C9 and CYP2C19, and has no clinically relevant effect on CYP2C8 (see INTERACTIONS WITH OTHER MEDICINES).
**Excretion**

The mean apparent clearance (CL/F) of enzalutamide in patients ranges from 0.520 and 0.564 L/h.

Following oral administration of $^{14}$C-enzalutamide, 84.6% of the radioactivity is recovered by 77 days post dose: 71.0% is recovered in urine (primarily as the inactive metabolite, with trace amounts of enzalutamide and the active metabolite), and 13.6% is recovered in faeces (0.39% of dose as unchanged enzalutamide).

**Linearity**

No major deviations from dose proportionality are observed over the dose range 40 to 160 mg. The steady-state $C_{min}$ values of enzalutamide and the active metabolite in individual patients remained constant during more than one year of chronic therapy, demonstrating time-linear pharmacokinetics once steady-state is achieved.

**Pharmacokinetic characteristics in special populations**

*Patients with hepatic impairment:* The pharmacokinetics of enzalutamide were examined in subjects with baseline mild (N = 6) or moderate (N = 8) hepatic impairment (Child-Pugh Class A and B, respectively) and in 14 matched control subjects with normal hepatic function. Following a single oral 160 mg dose of enzalutamide, the AUC and $C_{max}$ for enzalutamide in subjects with mild impairment increased by 5% and 24%, respectively, and the AUC and $C_{max}$ of enzalutamide in subjects with moderate impairment increased by 29% and decreased by 11%, respectively, compared to healthy control subjects. For the sum of unbound enzalutamide plus the unbound active metabolite, the AUC and $C_{max}$ in subjects with mild impairment increased by 14% and 19%, respectively, and the AUC and $C_{max}$ in subjects with moderate impairment increased by 14% and decreased by 17%, respectively, compared to healthy control subjects. The patients in the moderate hepatic impairment group however had only modest impairment in parameters indicative of metabolic function (albumin, prothrombin time), and thus a larger effect in other patients with moderate hepatic impairment cannot be excluded.

Patients with baseline severe hepatic impairment (Child-Pugh C) were excluded from clinical trials.

*Patients with renal impairment:* No formal renal impairment study for enzalutamide has been completed. Patients with serum creatinine > 177 µmol/L (2 mg/dL) were excluded from clinical trials. Based on a population pharmacokinetic analysis, no dose adjustment is necessary for patients with calculated creatinine clearance (CrCL) values ≥ 30 mL/min (estimated by the Cockcroft and Gault formula). Enzalutamide has not been evaluated in patients with severe renal impairment (CrCL < 30 mL/min) or end-stage renal disease, and caution is advised when treating these patients. It is unlikely that enzalutamide will be significantly removed by intermittent haemodialysis or continuous ambulatory peritoneal dialysis.

*Elderly:* No clinically relevant effect of age on enzalutamide pharmacokinetics was seen in the population pharmacokinetic analysis.
Paediatric use: Safety and efficacy of enzalutamide in paediatric patients have not been established.

Gender and race: The effect of gender on the pharmacokinetics of enzalutamide has not been evaluated. Most patients in the clinical trials (> 92%) were Caucasian, thus no conclusions on the impact of race on enzalutamide pharmacokinetics can be drawn.

CLINICAL TRIALS

The efficacy and safety of XTANDI in patients with metastatic castration-resistant prostate cancer who had received docetaxel and were using a gonadotropin-releasing hormone (GnRH) analogue or had undergone orchiectomy were assessed in a randomised, placebo-controlled, multicentre phase 3 clinical trial (AFFIRM). A total of 1199 patients were randomised 2:1 to receive either XTANDI orally at a dose of 160 mg once daily (N = 800) or placebo once daily (N = 399). Patients were allowed but not required to take prednisone (maximum daily dose allowed was 10 mg prednisone or equivalent). Patients randomised to either arm were to continue treatment until disease progression (defined as confirmed radiographic progression or the occurrence of a skeletal-related event) and initiation of new systemic antineoplastic treatment, unacceptable toxicity, or withdrawal. Following progression, 41% of study drug arm and 61.7% of placebo arm received ≥ 1 further systemic treatments therefore the observed survival data and Kaplan-Meier curve reflect a median duration of treatment of 8 months of enzalutamide vs 3 months of placebo followed by additional treatments.

The following patient demographics and baseline disease characteristics were balanced between the treatment arms. The median age was 69 years (range 41-92) and the racial distribution was 92.7% Caucasian, 3.9% Black, 1.1% Asian, and 2.1% Other. The ECOG performance score was 0-1 in 91.5% of patients and 2 in 8.5% of patients; 28.4% had a mean Brief Pain Inventory score of ≥ 4 (mean of patient’s reported worst pain over the previous 24 hours calculated for seven days prior to randomization). Most (91.2%) patients had metastases in bone and 23.2% had visceral lung and/or liver involvement. At study entry, 51% of randomized patients had PSA progression only, whereas 59% of patients had radiographic progression. 51% of patients were on bisphosphonates at baseline.

The phase 3 study excluded patients with medical conditions that may predispose them to seizures (see ADVERSE EFFECTS) and medications known to decrease the seizure threshold, as well as clinically significant cardiovascular disease such as uncontrolled hypertension, recent history of myocardial infarction or unstable angina, New York Heart Association class III or IV heart failure (unless ejection fraction was ≥ 45%), clinically significant ventricular arrhythmias or AV block (without permanent pacemaker).

Of the 800 patients in the phase 3 trial who received XTANDI, 568 patients (71%) were 65 years and over and 199 patients (25%) were 75 years and over. No overall differences in safety or effectiveness were observed between these elderly patients and younger patients.

The protocol pre-specified interim analysis after 520 deaths showed a statistically significant
superiority in overall survival in patients treated with XTANDI compared to placebo (Table 1 and Figure 1).
Table 1: Overall survival of patients treated with either XTANDI or placebo (intent-to-treat analysis)\(^a\)

<table>
<thead>
<tr>
<th></th>
<th>XTANDI (N = 800)</th>
<th>Placebo (N = 399)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deaths (%)</td>
<td>308 (38.5%)</td>
<td>212 (53.1%)</td>
</tr>
<tr>
<td>Median survival (months) (95% CI)</td>
<td>18.4 (17.3, NR)</td>
<td>13.6 (11.3, 15.8)</td>
</tr>
<tr>
<td>P-value(^b)</td>
<td>&lt; 0.0001</td>
<td></td>
</tr>
<tr>
<td>Hazard ratio (95% CI)(^c)</td>
<td>0.631 (0.529, 0.752)</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) Median duration of treatment of 8 months of enzalutamide vs 3 months of placebo followed by additional treatments.

\(^b\) P-value is derived from a log-rank test stratified by ECOG performance status score (0-1 vs. 2) and mean pain score (< 4 vs. \(\geq 4\))

\(^c\) Hazard ratio is derived from a stratified proportional hazards model. Hazard ratio < 1 favours XTANDI

Figure 1: Kaplan-Meier Overall Survival Curves (Intent-to-Treat Analysis)

Subgroup survival analysis showed a consistent survival benefit for treatment with XTANDI (see Figure 2)
In addition to the observed improvement in overall survival, key secondary endpoints (radiographic progression-free survival, and time to first skeletal-related event) favoured XTANDI and were statistically significant after adjusting for multiple testing.

Radiographic progression-free survival as assessed by the investigator using RECIST v1.1 for soft tissue and appearance of 2 or more bone lesions in bone scan was 8.3 months for patients treated with XTANDI and 2.9 months for patients who received placebo (HR = 0.404, 95% CI: [0.350, 0.466]); p < 0.0001). The analysis involved 216 deaths without documented progression and 645 documented progression events, of which 303 (47%) were due to soft tissue progression, 268 (42%) were due to bone lesion progression and 74 (11%) were due to both soft tissue and bone lesions.

The median time to first skeletal-related event was 16.7 months for patients treated with XTANDI and 13.3 months for patients who received placebo (HR = 0.688, 95% CI: [0.566, 0.835]; p < 0.0001). A skeletal-related event was defined as radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression, or change of antineoplastic therapy to treat bone pain.

The efficacy of enzalutamide in patients who have previously received abiraterone acetate has not been studied.
INDICATIONS

XTANDI is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.

CONTRAINDICATIONS

XTANDI is contraindicated in patients with known hypersensitivity to enzalutamide or to any of the excipients in the formulation.

XTANDI is contraindicated in women who are, or may become, pregnant. (see PRECAUTIONS – Contraception in males and females, and Use in pregnancy)

PRECAUTIONS

XTANDI capsules should only be prescribed by a medical practitioner who is experienced with the treatment of prostate cancer and the use of antineoplastic endocrine therapies.

The following are clinically significant: seizures (see Risk of seizure below) and drug interactions (see INTERACTIONS WITH OTHER MEDICINES).

Risk of seizure

The risk to patients, especially those with predisposing factors for seizures has not been studied and is unknown. In the randomized clinical trial, 7 of 800 (0.9%) patients treated with XTANDI 160 mg once daily experienced a seizure. No seizures occurred in patients treated with placebo. Because of the risk of seizure associated with XTANDI use, patients should be advised of the risk of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others.

Caution should be used in administering XTANDI to patients with a history of seizures or other predisposing factors including, but not limited to, underlying brain injury, stroke, primary brain tumours or brain metastases, or alcoholism. In addition, the risk of seizure may be increased in patients receiving concomitant medicines that lower the seizure threshold.

Renal impairment

Caution is required in patients with severe renal impairment as XTANDI has not been studied in this patient population.

Hepatic impairment

No dose adjustment is required for mild hepatic impairment (Child-Pugh Class A). Caution is advised in patients with moderate hepatic impairment (Child-Pugh Class B; see PHARMACOLOGY – Pharmacokinetic characteristics in special populations) and XTANDI is not recommended in patients with severe hepatic impairment (Child-Pugh Class C).

Recent cardiovascular disease
The AFFIRM study excluded patients with recent myocardial infarction (in the past 6 months)
or unstable angina (in the past 3 months), New York Heart Association (NYHA) Class III or IV heart failure except if Left Ventricular Ejection Fraction (LVEF) ≥ 45%, long QT, QTcF > 470 ms, bradycardia or uncontrolled hypertension. This should be taken into account if XTANDI is prescribed in these patients.

Use with chemotherapy

The safety and efficacy of concomitant use of XTANDI with cytotoxic chemotherapy has not been established.

Contraception in males and females

As it is not known whether XTANDI or its metabolites are present in semen, and there were severe teratogenic effects observed in the animal studies, a condom is required during and for 3 months after treatment with XTANDI if the patient is engaged in sexual activity with a pregnant woman. If the patient engages in sexual intercourse with a woman of childbearing potential, a condom and another form of birth control must be used during and for 3 months after treatment. Studies in animals have shown reproductive toxicity (see PRECAUTIONS – Effects on fertility and Use in pregnancy).

Effects on fertility

Based on its pharmacology and findings in animal studies, male fertility may be impaired by treatment with enzalutamide. Findings in the male reproductive tract of rats and/or dogs treated with enzalutamide included atrophy of the prostate gland and seminal vesicles, testicular hypospermia and seminiferous tubule degeneration. These effects were observed at all dose levels (below the clinical exposure based on AUC) and reversed or partially resolved after an 8-week recovery period.

Use in pregnancy (Category X)

Category X - Drugs which have such a high risk of causing permanent damage to the fetus that they should not be used in pregnancy or when there is a possibility of pregnancy.

XTANDI is not indicated for use in women of child-bearing potential. XTANDI has not been shown to be safe for use in women. XTANDI is contraindicated in women who are or may become pregnant (see CONTRAINDICATIONS). There are no human data on the use of XTANDI in pregnancy. Teratogenicity (cleft palate, cervical rib and decreased anogenital distance) and embryo-fetal lethality were seen in a mouse embryo-fetal development study at >10 mg/kg/day (below the clinical exposure based on AUC).

Use in lactation

XTANDI is not indicated for use in women and has not been shown to be safe in children. It is not known whether XTANDI is secreted in human milk.

Paediatric use
The safety of XTANDI has not been studied in children, and therefore it is not recommended for use in those <18 years of age.

Use in the elderly

No clinically relevant effect of age on XTANDI pharmacokinetics was seen in the population pharmacokinetic analysis. No dose adjustment is required for the elderly.

Genotoxicity

Enzalutamide did not induce mutations in the microbial mutagenesis (Ames) assay and was not clastogenic in either the in vitro cytogenetic assay with mouse lymphoma cells or the in vivo mouse micronucleus assay.

Carcinogenicity

Long-term animal studies to evaluate the carcinogenic potential of enzalutamide have not been conducted.

Effect on laboratory tests

There is no information on the effect of enzalutamide on laboratory tests.

Effects on ability to drive and use machines

Neurological and psychiatric events have occurred in patients taking XTANDI (see ADVERSE EFFECTS). No formal studies of the effects of XTANDI on the ability to drive or use machines have been conducted. Patients with a history of seizures or other predisposing factors (see PRECAUTIONS – Risk of seizure, and INTERACTIONS WITH OTHER MEDICINES) should be advised of the risk of driving or operating machines.

INTERACTIONS WITH OTHER MEDICINES

Effects of other medicines on XTANDI

CYP2C8 inhibitors and inducers

CYP2C8 plays an important role in the elimination of enzalutamide and in the formation of its active metabolite. Following oral administration of the strong CYP2C8 inhibitor gemfibrozil (600 mg twice daily) to healthy male subjects, the AUC of the sum of enzalutamide plus the active metabolite increased by 2.17-fold while $C_{\text{max}}$ decreased by 16%  Strong inhibitors (e.g. gemfibrozil) or inducers (e.g. rifampicin) of CYP2C8 are to be avoided or used with caution during enzalutamide treatment. If patients must be co-administered a strong CYP2C8 inhibitor, the dose of enzalutamide should be reduced to 80 mg once daily  (see DOSAGE AND ADMINISTRATION).

CYP3A4 inhibitors and inducers

CYP3A4 plays a minor role in the metabolism of enzalutamide. Following oral administration of the strong CYP3A4 inhibitor itraconazole (200 mg once daily) to healthy male subjects, the
AUC of enzalutamide increased by 41% while $C_{\text{max}}$ was unchanged. For the sum of unbound enzalutamide plus the unbound active metabolite, the AUC increased by 27% while $C_{\text{max}}$ was again unchanged. No dose adjustment is necessary when enzalutamide is co-administered with inhibitors or inducers of CYP3A4.

Effects of XTANDI on other medicines

**Enzyme induction**
Enzalutamide is a potent enzyme inducer and increases the synthesis of many enzymes and transporters; therefore, interaction with many common medicinal products that are substrates of enzymes or transporters is expected. The reduction in plasma concentrations can be substantial, and lead to lost or reduced clinical effect. There is also a risk of increased formation of active metabolites. Enzymes that may be induced include CYP3A in the liver and gut, CYP2C9, CYP2C19 and uridine 5'-diphospho-glucuronosyltransferase (UGTs - glucuronide conjugating enzymes). The transport protein P-gp may also be induced, and probably other transporters as well, e.g. multidrug resistance-associated protein 2 (MRP2), breast cancer resistant protein (BCRP) and the organic anion transporting polypeptide 1B1 (OATP1B1).

In vivo studies have shown that enzalutamide is a strong inducer of CYP3A4 and a moderate inducer of CYP2C9 and CYP2C19. Co-administration of enzalutamide (160 mg once daily) with single oral doses of sensitive CYP substrates in prostate cancer patients resulted in an 86% decrease in the AUC of midazolam (CYP3A4 substrate), a 56% decrease in the AUC of S-warfarin (CYP2C9 substrate), and a 70% decrease in the AUC of omeprazole (CYP2C19 substrate). UGT1A1 may have been induced as well.

Interactions with certain medicinal products that are eliminated through metabolism or active transport are expected. If their therapeutic effect is of large importance to the patient, and dose adjustments are not easily performed based on monitoring of efficacy or plasma concentrations, these medicinal products are to be avoided or used with caution.

**The risk for liver injury after paracetamol administration is suspected to be higher in patients concomitantly treated with enzyme inducers.**

Groups of medicinal products that can be affected include, but are not limited to:

- Analgesics (e.g. fentanyl, tramadol)
- Antibiotics (e.g. clarithromycin, doxycycline)
- Anticancer agents (e.g. cabazitaxel)
- Anticoagulants (e.g. warfarin)
- Antiepileptics (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid)
- Antipsychotics (e.g. haloperidol)
- Betablockers (e.g. bisoprolol, propanolol)
- Calcium channel blockers (e.g. diltiazem, felodipine, nicardipine, nifedipine, verapamil)
- Cardiac glycosides (e.g. digoxin)
- Corticosteroids (e.g. dexamethasone, prednisolone)
- HIV antivirals (e.g. indinavir, ritonavir)
- Hypnotics (e.g. diazepam, midazolam, zolpidem)
• Statins metabolized by CYP3A4 (e.g. atorvastatin, simvastatin)
• Thyroid agents (e.g. levothyroxine)
The full induction potential of enzalutamide may not occur until approximately 1 month after the start of treatment, when steady-state plasma concentrations of enzalutamide are reached, although some induction effects may be apparent earlier. Patients taking drugs that are substrates of CYP3A4, CYP2C9, CYP2C19 or UGT1A1 should be evaluated for possible loss of pharmacological effects (or increase in effects in cases where active metabolites are formed) during the first month of XTANDI treatment, and dose adjustment should be considered as appropriate. In consideration of the long half-life of enzalutamide (5.8 days, see PHARMACOLOGY – Pharmacokinetics), effects on enzymes may persist for one month or longer after stopping XTANDI. A gradual dose reduction of the concomitant medicinal product may be necessary when stopping XTANDI treatment.

**Warfarin and coumarin-like anticoagulants**
Co-administration with warfarin and coumarin-like anticoagulants should be avoided. If XTANDI is coadministered with an anticoagulant metabolized by CYP2C9 (such as warfarin), additional INR monitoring should be conducted.

**CYP2C8 substrates**
Enzalutamide (160 mg once daily) did not cause a clinically relevant change in the AUC or C\text{max} of pioglitazone (CYP2C8 substrate). The AUC of pioglitazone increased by 20% while C\text{max} decreased by 18%. No dose adjustment is indicated when a CYP2C8 substrate is co-administered with XTANDI.

**P-gp substrates**
*In vitro* data indicate that enzalutamide is not a substrate for, but may be an inhibitor of the efflux transporter P-gp. The effect of enzalutamide on P-gp substrates has not been evaluated *in vivo*; however, under conditions of clinical use, enzalutamide may be an inducer of P-gp via activation of the nuclear pregnane receptor (PXR). Medicinal products with a narrow therapeutic range that are substrates for P-gp (e.g. colchicine, dabigatran etexilate, digoxin) should be used with caution when administered concomitantly with XTANDI and may require dose adjustment to maintain optimal plasma concentrations.

**BCRP, MRP2, OAT1, OAT3, OATP1B1, OATP1B3, OCT1 and OCT2 substrates**
Based on *in vitro* data, inhibition of BCRP and MRP2 (in the intestine), as well as organic anion transporter 3 (OAT3), OATP1B1, and OCT1 (systemically) cannot be excluded. Theoretically, induction of OAT3, OATP1B1, OCT1, BCRP and MRP2 is also possible, and the net effect is presently unknown. The effects of enzalutamide on these transporters have not been evaluated *in vivo*. *In vitro* data indicate that enzalutamide and its major metabolites do not inhibit the following transporters at clinically relevant concentrations: OAT1, OATP1B3, or OCT2.

**Effect of food on XTANDI exposures**
Food has no clinically significant effect on the extent of exposure to XTANDI. In clinical trials, XTANDI was administered without regard to food.

**ADVERSE EFFECTS**

**Clinical trial experience**
In the randomized, placebo-controlled, phase 3 clinical trial (AFFIRM) in patients with metastatic castration-resistant prostate cancer who had previously received docetaxel, patients received XTANDI 160 mg orally once daily (N = 800) or placebo (N = 399). The median duration of treatment was 8.3 months with XTANDI and 3.0 months with placebo. All patients continued androgen deprivation therapy. Patients were allowed, but not required, to take glucocorticoids. During the trial, 48% of patients on the XTANDI arm and 46% of patients on the placebo arm received glucocorticoids. All adverse events and laboratory abnormalities were graded using NCI CTCAE version 4.

The most common adverse drug reactions (≥ 5%) reported in patients receiving XTANDI in the randomized clinical trial were asthenia/fatigue, back pain, diarrhoea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and hypertension. Grade 3 and higher adverse reactions were reported among 47% of XTANDI-treated patients and 53% of placebo-treated patients. Discontinuations due to adverse events were reported for 16% of XTANDI-treated patients and 18% of placebo-treated patients. The most common adverse reaction leading to treatment discontinuation was seizure, which occurred in 0.9% of the XTANDI-treated patients compared to none (0%) of the placebo-treated patients. Table 1 shows adverse reactions reported in the randomized clinical trial that occurred at a ≥ 2% absolute increase in frequency in the XTANDI arm compared to the placebo arm.

### Table 1. Adverse Reactions in the Randomized Trial (AFFIRM)

<table>
<thead>
<tr>
<th></th>
<th>XTANDI N = 800</th>
<th></th>
<th>Placebo N = 399</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grade 1-4 (%)</td>
<td>Grade 3-4 (%)</td>
<td>Grade 1-4 (%)</td>
<td>Grade 3-4 (%)</td>
</tr>
<tr>
<td><strong>General Disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenic Conditions</td>
<td>50.6</td>
<td>9.0</td>
<td>44.4</td>
<td>9.3</td>
</tr>
<tr>
<td>Peripheral Edema</td>
<td>15.4</td>
<td>1.0</td>
<td>13.3</td>
<td>0.8</td>
</tr>
<tr>
<td><strong>Musculoskeletal And Connective Tissue Disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Back Pain</td>
<td>26.4</td>
<td>5.3</td>
<td>24.3</td>
<td>4.0</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>20.5</td>
<td>2.5</td>
<td>17.3</td>
<td>1.8</td>
</tr>
<tr>
<td>Musculoskeletal Pain</td>
<td>15.0</td>
<td>1.3</td>
<td>11.5</td>
<td>0.3</td>
</tr>
<tr>
<td>Muscular Weakness</td>
<td>9.8</td>
<td>1.5</td>
<td>6.8</td>
<td>1.8</td>
</tr>
<tr>
<td>Musculoskeletal Stiffness</td>
<td>2.6</td>
<td>0.3</td>
<td>0.3</td>
<td>0.0</td>
</tr>
<tr>
<td><strong>Gastrointestinal Disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>21.8</td>
<td>1.1</td>
<td>17.5</td>
<td>0.3</td>
</tr>
<tr>
<td><strong>Vascular Disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hot Flush</td>
<td>20.3</td>
<td>0.0</td>
<td>10.3</td>
<td>0.0</td>
</tr>
<tr>
<td>Hypertension</td>
<td>6.4</td>
<td>2.1</td>
<td>2.8</td>
<td>1.3</td>
</tr>
<tr>
<td><strong>Nervous System Disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>12.1</td>
<td>0.9</td>
<td>5.5</td>
<td>0.0</td>
</tr>
<tr>
<td>Dizziness</td>
<td>9.5</td>
<td>0.5</td>
<td>7.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Spinal Cord Compression and Cauda Equina</td>
<td>7.4</td>
<td>6.6</td>
<td>4.5</td>
<td>3.8</td>
</tr>
</tbody>
</table>
### XTANDI N = 800

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Placebo N = 399</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1-4 (%)</td>
<td>Grade 3-4 (%)</td>
</tr>
<tr>
<td></td>
<td>Grade 1-4 (%)</td>
</tr>
<tr>
<td>Paresthesia</td>
<td>6.6</td>
</tr>
<tr>
<td>Mental Impairment</td>
<td>4.3</td>
</tr>
<tr>
<td>Disoders(^c)</td>
<td>4.5</td>
</tr>
<tr>
<td>Hypoesthesia</td>
<td>4.0</td>
</tr>
</tbody>
</table>

### Infections And Infestations

<table>
<thead>
<tr>
<th>Infections And Infestations</th>
<th>XTANDI (N = 800)</th>
<th>Placebo (N = 399)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1-4 (%)</td>
<td>Grade 3-4 (%)</td>
<td></td>
</tr>
<tr>
<td>Upper Respiratory Tract</td>
<td>10.9</td>
<td>0.0</td>
</tr>
<tr>
<td>Infection(^d)</td>
<td>6.5</td>
<td>0.3</td>
</tr>
<tr>
<td>Lower Respiratory Tract</td>
<td>8.5</td>
<td>2.4</td>
</tr>
<tr>
<td>And Lung Infection(^e)</td>
<td>4.8</td>
<td>1.3</td>
</tr>
</tbody>
</table>

### Psychiatric Disorders

<table>
<thead>
<tr>
<th>Psychiatric Disorders</th>
<th>XTANDI (N = 800)</th>
<th>Placebo (N = 399)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1-4 (%)</td>
<td>Grade 3-4 (%)</td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>8.8</td>
<td>0.0</td>
</tr>
<tr>
<td>Anxiety</td>
<td>6.5</td>
<td>0.3</td>
</tr>
<tr>
<td>Hematuria</td>
<td>6.9</td>
<td>1.8</td>
</tr>
<tr>
<td>Pollakiuria</td>
<td>4.8</td>
<td>0.0</td>
</tr>
</tbody>
</table>

### Renal And Urinary Disorders

<table>
<thead>
<tr>
<th>Renal And Urinary Disorders</th>
<th>XTANDI (N = 800)</th>
<th>Placebo (N = 399)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1-4 (%)</td>
<td>Grade 3-4 (%)</td>
<td></td>
</tr>
<tr>
<td>Fall</td>
<td>4.6</td>
<td>0.3</td>
</tr>
<tr>
<td>Non-pathologic Fractures</td>
<td>4.0</td>
<td>1.4</td>
</tr>
</tbody>
</table>

### Injury, Poisoning And Procedural Complications

<table>
<thead>
<tr>
<th>Injury, Poisoning And Procedural Complications</th>
<th>XTANDI (N = 800)</th>
<th>Placebo (N = 399)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1-4 (%)</td>
<td>Grade 3-4 (%)</td>
<td></td>
</tr>
<tr>
<td>Pruritus</td>
<td>3.8</td>
<td>0.0</td>
</tr>
<tr>
<td>Dry Skin</td>
<td>3.5</td>
<td>0.0</td>
</tr>
</tbody>
</table>

### Skin And Subcutaneous Tissue Disorders

<table>
<thead>
<tr>
<th>Skin And Subcutaneous Tissue Disorders</th>
<th>XTANDI (N = 800)</th>
<th>Placebo (N = 399)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1-4 (%)</td>
<td>Grade 3-4 (%)</td>
<td></td>
</tr>
<tr>
<td>Epistaxis</td>
<td>3.3</td>
<td>0.1</td>
</tr>
</tbody>
</table>

### Respiratory Disorders

<table>
<thead>
<tr>
<th>Respiratory Disorders</th>
<th>XTANDI (N = 800)</th>
<th>Placebo (N = 399)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1-4 (%)</td>
<td>Grade 3-4 (%)</td>
<td></td>
</tr>
<tr>
<td>Epistaxis</td>
<td>3.3</td>
<td>0.1</td>
</tr>
</tbody>
</table>

The following additional adverse reactions were reported during the AFFIRM trial and are listed by frequency category. Frequency categories are defined as follows: very common reactions are defined as those occurring in ≥10% of patients, common reactions are defined as those occurring in ≥1% and <10% of patients, uncommon reactions are defined as those occurring in ≥0.1% and <1% of patients, and rare reactions are defined as those occurring in <0.1% of patients.

### Blood and lymphatic system disorders

- **Common**: neutropenia
- **Uncommon**: leucopenia

### Psychiatric disorders

- **Common**: visual hallucinations

---

\(^a\) Includes asthenia and fatigue.

\(^b\) Includes dizziness and vertigo.

\(^c\) Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention.

\(^d\) Includes nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis.

\(^e\) Includes pneumonia, lower respiratory tract infection, bronchitis, and lung infection.
Nervous system disorders
Uncommon: seizure
Description of selected adverse reactions

Seizures
In the AFFIRM trial, 7 of 800 (0.9%) patients treated with XTANDI 160 mg once daily experienced a seizure. No seizures occurred in patients treated with placebo. Seizures occurred from 31 to 603 days after initiation of XTANDI. Patients experiencing seizure were permanently discontinued from therapy and all seizures resolved. There is no clinical trial experience re-administering XTANDI to patients who experienced seizures. Seizure reactions identified during the post-marketing experience based on spontaneous reports with XTANDI demonstrate a frequency of ≥0.1% and <1% (Uncommon).

Laboratory abnormalities
In the AFFIRM trial, Grade 1-4 neutropenia occurred in 15% of patients on XTANDI (1% Grade 3-4) and in 6% of patients on placebo (no Grade 3-4). The incidence of Grade 1-4 thrombocytopenia was similar in both arms; 0.5% of patients on XTANDI and 1% on placebo experienced Grade 3-4 thrombocytopenia. Grade 1-4 elevations in ALT occurred in 10% of patients on XTANDI (0.3% Grade 3-4) and 18% of patients on placebo (0.5% Grade 3-4). Grade 1-4 elevations in bilirubin occurred in 3% of patients on XTANDI and 2% of patients on placebo.

Infections
In the AFFIRM trial, 1.0% of patients treated with XTANDI compared to 0.3% of patients on placebo died from infections or sepsis. Infection-related serious adverse events were reported in approximately 6% of the patients on both treatment arms.

Falls and fall-related injuries
In the AFFIRM trial, falls or injuries related to falls occurred in 4.6% of patients treated with XTANDI compared to 1.3% of patients on placebo. Falls were not associated with loss of consciousness or seizure. Fall-related injuries were more severe in patients treated with XTANDI and included non-pathologic fractures, joint injuries, and hematomas. For patients who fall or have a concomitant recognised risk of falling, it is recommended that the physicians consider additional supportive therapy when appropriate.

Hallucinations
In the AFFIRM trial, 1.6% of patients treated with XTANDI were reported to have Grade 1 or 2 hallucinations compared to 0.3% of patients on placebo. Of the patients with hallucinations, the majority were on opioid-containing medications at the time of the event. Hallucinations were visual, tactile, or undefined.

DOSAGE AND ADMINISTRATION
The recommended dose of XTANDI is 160 mg (four 40 mg capsules) as a single oral daily dose. Swallow capsules whole with water. Do not chew, dissolve, or open the capsules.

XTANDI can be taken with or without food.
If a patient experiences a ≥ Grade 3 toxicity or an intolerable adverse reaction, withhold dosing for one week or until symptoms improve to ≤ Grade 2, then resume at the same or a reduced dose (120 mg or 80 mg) if warranted.

**Concomitant use with strong CYP2C8 inhibitors**

The concomitant use of strong CYP2C8 inhibitors should be avoided if possible. If patients must be co-administered a strong CYP2C8 inhibitor, reduce the dose of XTANDI to 80 mg once daily. If co-administration of the strong CYP2C8 inhibitor is discontinued, the XTANDI dose should be returned to the dose used prior to initiation of the strong CYP2C8 inhibitor (see INTERACTIONS WITH OTHER MEDICINES).

**Patients with hepatic impairment**

No dose adjustment is required for mild hepatic impairment (Child-Pugh Class A). Caution is advised in patients with moderate hepatic impairment (Child-Pugh Class B; see PHARMACOLOGY – Pharmacokinetic characteristics in special populations) and XTANDI is not recommended in patients with severe hepatic impairment (Child-Pugh Class C).

**Patients with renal impairment**

No dose adjustment is necessary for patients with mild or moderate renal impairment (see PHARMACOLOGY - Pharmacokinetic characteristics in special populations). Caution is advised in patients with severe renal impairment or end-stage renal disease (see PRECAUTIONS – Renal impairment).

**OVERDOSAGE**

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

There is no antidote for XTANDI. In the event of an overdose, treatment with XTANDI should be stopped and general supportive measures initiated taking into consideration the half-life of 5.8 days. Patients may be at increased risk of seizures following an overdose.

**PRESENTATION AND STORAGE CONDITIONS**

XTANDI 40 mg capsules are supplied as white to off-white oblong soft gelatin capsules imprinted with “ENZ” in black ink on one side.

XTANDI 40 mg capsules are supplied in a cardboard wallet incorporating a PVC/PCTFE/aluminium blister of 28 soft capsules. Each carton contains 4 wallets (112 soft capsules).

**Storage conditions**

Store below 25°C.
NAME AND ADDRESS OF THE SPONSOR

Astellas Pharma Australia Pty Ltd
Level 4, 6 Eden Park Drive
Macquarie Park
NSW 2113
Australia

POISON SCHEDULE OF THE MEDICINE

Schedule 4 – Prescription Only Medicine

DATE OF FIRST INCLUSION IN THE AUSTRALIAN REGISTER OF THERAPEUTIC GOODS (THE ARTG)

1 July 2014